Cinclus Pharma Holding publ AB

CINPHA.ST · N/A · SE

cincluspharma.com

About

Cinclus Pharma Holding publ AB develops linaprazan glurate, a small molecule treatment for severe gastroesophageal reflux disease (GERD), underpinned by its mission to impact standard of care for gastric acid related diseases. The company owns worldwide commercial rights for linaprazan glurate, securing the process of launching the product globally. As a research-based biotech company in an intensive development phase, Cinclus Pharma is ramping up its organization and company structure to prepare for growth and further development of linaprazan glurate. Cinclus Pharma targets patients with gastric acid related diseases through its focus on superior P-CAB linaprazan glurate, aiming to introduce products that improve standard of care. The firm's development phase involves building a structure to support global market entry and commercialization of linaprazan glurate, with secured commercial rights enabling worldwide launches. The company's revenue model relies on the future commercialization of linaprazan glurate after successful development and regulatory approval. The business model centers on developing linaprazan glurate as a treatment for severe GERD, leveraging its P-CAB mechanism to position it as a superior alternative in gastric acid related disease management. Cinclus Pharma's strategy includes securing worldwide commercial rights and preparing for market entry through organizational scaling, with the product's success dependent on regulatory milestones and market adoption of linaprazan glurate.

Annual results

Reported figures, SEK · revenue up 1325.0% in 2025

YearRevenueNet incomeNet marginFree cash flow
202557.0M-183M-321.1%—
20244.0M-168M-4200.0%—
20235.0M-215M-4300.0%—
202210.0M-249M-2490.0%—

CINPHA.ST in MarketPulse

The live chart with RSI and moving averages, the price, news, signals and price alerts for Cinclus Pharma Holding publ AB are inside MarketPulse — currently in private beta.

Company data by Eulerpool. Logos provided by Elbstream. Reported figures, not investment advice.

Cinclus Pharma Holding publ AB (CINPHA.ST) — company profile and financials · MarketPulse